Announcing Olink Explore HT – A New Era in Proteomics

A High-throughput Protein Biomarker Discovery Platform with Proven Specificity at Any Scale

UPPSALA, Sweden, July 12, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Explore HT, a transformational solution for high-throughput proteomics delivering unmatched specificity, scalability, and workflow simplicity.

Olink Explore HT represents a significant advancement in next generation proteomics, allowing scientists to accurately measure over 5,300 proteins using only 2µl of sample with a completely reimagined and streamlined workflow, including a highly automated data analysis platform. In addition to delivering over 80% more unique protein assays than the previous generation product, Olink Explore HT increases sample throughput by 4X and data output by 7X with a >30% reduction in cost per data point and >20% reduction in workflow processing cost. Importantly, these innovations substantially reduce the environmental footprint with a 6-fold decrease in components and 10-fold reduction in boxes.

“Olink Explore HT demonstrates our unwavering commitment to innovation and delivering the most powerful solutions for scientific research,” said Jon Heimer, CEO of Olink. “The power and capability of Olink Explore HT seemed almost unthinkable just a handful of years ago. This is the most advanced high-throughput proteomics product Olink has ever offered, and the unmatched performance will empower new discoveries critical for 21^st century healthcare.”

Olink Explore HT was designed to unlock the immense value of proteomics at any scale and advance multi-omic research. It can be utilized across a wide range of therapeutic areas to deepen current understanding of molecular pathways involved in the development, progression, and outcome of disease. Olink Explore HT will also empower new discoveries in drug development, from target discovery based on identification of proteins causal in disease, to actionable insights into mode of action studies and repurposing of therapeutics from reinterrogation of existing samples from clinical trials.

“We are very excited about the new Olink Explore HT platform. With Olink’s transformative multiplex PEA technology, Olink Explore HT allows us to perform high-throughput, highly multiplexed and extremely precise protein analysis from minute amounts of clinical sample,” said Ulf Gyllensten, Professor of Medical Molecular Genetics at Uppsala University, Sweden. “Coupling PEA with an NGS readout conveys Olink Explore HT with unprecedented power to unveil the human proteome. As early access users, we have successfully used the platform to identify diagnostic and prognostic biomarkers for gynecological cancer. The expanded set of proteins available for analysis with Olink Explore HT will certainly accelerate the discovery of other novel biomarkers and reveal important new biological insights. More broadly, the platform unlocks a powerful multiomics-based approach across the entire drug development process, from basic to translational research.”